TY - JOUR
T1 - The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2T Cells
AU - Sandstrom, Andrew
AU - Peigné, Cassie Marie
AU - Léger, Alexandra
AU - Crooks, James E.
AU - Konczak, Fabienne
AU - Gesnel, Marie Claude
AU - Breathnach, Richard
AU - Bonneville, Marc
AU - Scotet, Emmanuel
AU - Adams, Erin J.
N1 - Funding Information:
We thank the staff of the Advanced Proton Source at GM/CA-CAT (23-ID) and NE-CAT (24-ID) for their use and assistance with X-ray beamlines and R. Sanishvili, C. Ogata, and K. Perry in particular for help and advice during data collection. We thank M.S. Gu, A. Luoma, and C. Palka for advice and helpful discussions. A.S. designed and performed ITC experiments, mutagenesis, and protein crystallization and structure determination and handled manuscript preparation. We thank the staff of the Cytometry Facility (Cytocell) and Cellular and Tissular Imaging Core Facility (MicroPICell) of Nantes University for technical assistance, and Q. Amossé and S. Nedellec in particular for microscopy data collection and expert advice. We also thank C. Belmant (Innate Pharma) for kindly providing reagents. R.B., M.-C.G., F.K., C.-M.P., and A.L. designed and performed experiments involving mutagenesis and functional assays. E.J.A., M.B., and E.S. led the investigation and contributed to experiment design, data interpretation, and manuscript preparation. This work was supported by NIH grants R56_AI097386 and R01_AI073922 to E.J.A.; INSERM, Université de Nantes, Association pour la Recherche contre le Cancer (#R10139NN), Institut National du Cancer (#V9V2THER), Agence Nationale de la Recherche (#GDSTRESS), and Ligue Nationale contre le Cancer and Investissements d’Avenir (Agence Nationale de la Recherche-Programme Laboratoires d’Excellence Immunotherapy Graft Oncology). M.B. is a founding scientist of the company Innate Pharma SA and was a consultant for this company until October 2013. He is currently vice president of the Institut Merieux in charge of scientific and medical affairs.
PY - 2014/4/17
Y1 - 2014/4/17
N2 - In humans, Vγ9Vδ2 Tcells detect tumor cells and microbial infections, including Mycobacterium tuberculosis, through recognition of small pyrophosphate containing organic molecules known as phosphoantigens (pAgs). Key to pAg-mediated activation ofVγ9Vδ2 Tcells is the butyrophilin 3A1 (BTN3A1) protein that contains an intracellular B30.2 domain critical to pAg reactivity. Here, we have demonstrated through structural, biophysical, and functional approaches that the intracellular B30.2 domain of BTN3A1 directly binds pAg through a positively charged surface pocket. Charge reversal of pocket residues abrogates binding and Vγ9Vδ2 Tcell activation. We have also identified a gain-of-function mutation within this pocket that, when introduced into the B30.2 domain of the nonstimulatory BTN3A3 isoform, transfers pAg binding ability and Vγ9Vδ2 Tcell activation. These studies demonstrate that internal sensing of changes in pAg metabolite concentrations by BTN3A1 molecules is a critical step in Vγ9Vδ2 Tcell detection of infection and tumorigenesis.
AB - In humans, Vγ9Vδ2 Tcells detect tumor cells and microbial infections, including Mycobacterium tuberculosis, through recognition of small pyrophosphate containing organic molecules known as phosphoantigens (pAgs). Key to pAg-mediated activation ofVγ9Vδ2 Tcells is the butyrophilin 3A1 (BTN3A1) protein that contains an intracellular B30.2 domain critical to pAg reactivity. Here, we have demonstrated through structural, biophysical, and functional approaches that the intracellular B30.2 domain of BTN3A1 directly binds pAg through a positively charged surface pocket. Charge reversal of pocket residues abrogates binding and Vγ9Vδ2 Tcell activation. We have also identified a gain-of-function mutation within this pocket that, when introduced into the B30.2 domain of the nonstimulatory BTN3A3 isoform, transfers pAg binding ability and Vγ9Vδ2 Tcell activation. These studies demonstrate that internal sensing of changes in pAg metabolite concentrations by BTN3A1 molecules is a critical step in Vγ9Vδ2 Tcell detection of infection and tumorigenesis.
UR - http://www.scopus.com/inward/record.url?scp=84899121545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899121545&partnerID=8YFLogxK
U2 - 10.1016/j.immuni.2014.03.003
DO - 10.1016/j.immuni.2014.03.003
M3 - Article
C2 - 24703779
AN - SCOPUS:84899121545
SN - 1074-7613
VL - 40
SP - 490
EP - 500
JO - Immunity
JF - Immunity
IS - 4
ER -